Rhopressa™ (netarsudil ophthalmic solution) 0.02%
Rocket 4 Phase 3
6-Month Topline Results

Important Information

Any discussion of the potential use or expected success of our product candidates is subject to our product candidates being approved by regulatory authorities.

The information in this presentation is current only as of its date and may have changed or may change in the future. We undertake no obligation to update this information in light of new information, future events or otherwise. We are not making any representation or warranty that the information in this presentation is accurate or complete.

Certain statements in this presentation are “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “will,” “should,” “would,” “could,” “believe,” “expects,” “anticipates,” “plans,” “intends,” “estimates,” “targets,” “projects,” “potential” or similar expressions are intended to identify these forward-looking statements. These statements are based on the Company’s current plans and expectations. Known and unknown risks, uncertainties and other factors could cause actual results to differ materially from those contemplated by the statements. In evaluating these statements, you should specifically consider various factors that may cause our actual results to differ materially from any forward-looking statements. These risks and uncertainties are described more fully in the quarterly and annual reports that we file with the SEC, particularly in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” In particular, the topline Rocket 4 data presented herein is preliminary and based solely on information available to us as of the date of this presentation and additional information about the results may be disclosed at any time. Such forward-looking statements only speak as of the date they are made. We undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise, except as otherwise required by law.

Rhopressa™ Achieves Positive 6-Month Safety and Efficacy Results

- Safety data over the 6 months were consistent with observations in previous Rhopressa™ 3-month and 12-month Phase 3 clinical trials
- There were no drug-related serious adverse events and no evidence of treatment-related systemic effects
- The main adverse event for Rhopressa™ was conjunctival hyperemia, which was reported in ~48% of patients, scored as mild for ~75% of the patients and sporadic
- Rhopressa™ achieved primary efficacy endpoint at month 3 and performance at months 4, 5 and 6 remained within the non-inferiority range compared to timolol at baseline IOPs < 25 mmHg, and also < 27 mmHg
- Rhopressa™ demonstrated stable and consistent efficacy across all baseline IOPs in the trial from Week 2 to Month 6 across multiple statistical analyses (PP/ITT/LOCF)

Rocket 4 Trial Design

Patients with open angle glaucoma (OAG) or ocular hypertension (OHT) with IOP >20 mmHg and < 30 mmHg at 8am,

N=708 subjects randomized at 52 US sites



Primary endpoints:

- Efficacy: Mean IOP at Weeks 2 and 6 and Month 3 for subjects with baseline IOP > 20 mmHg and <25 mmHg
  (N= 423 subjects per protocol)
- Safety: Ocular and systemic safety during a 6-month treatment period

ClinicalTrials.gov Identifier: NCT02558374

Patient Disposition (Topline 6-Month)

	Rhopressa™ QD N = 351	Timolol BID N = 357
Completed Month 6	**243 (69.2%)**	**314 (88.0%)**
Discontinued Prior to Month 6	**108 (30.8%)**	**43 (12.0%)**
Discontinued		
Adverse Event	68 (19.4%)	8 (2.2%)
Withdrawal of Consent	12 (3.4%)	16 (4.5%)
Non-Compliant	1 (0.3%)	2 (0.6%)
Lost to Follow-up	1 (0.3%)	3 (0.8%)
Lack of Efficacy	12 (3.4%)	1 (0.3%)
Disallowed Concurrent Medication	1 (0.3%)	3 (0.8%)
Investigator Decision	2 (0.6%)	4 (1.1%)
Protocol Violation	5 (1.4%)	4 (1.1%)
Other	6 (1.7%)	2 (0.6%)

++Data on File
Based on Rocket 4 Topline 6-month safety

Patient Disposition (Topline 6-Month) (For Baseline IOP <25mmHg)

	Rhopressa™ QD N = 214	Timolol BID N = 209
Completed Month 6	**160 (74.8%)**	**188 (90.0%)**
Discontinued Prior to Month 6	**54 (25.2%)**	**21 (10.0%)**
Discontinued		
Adverse Event	34 (15.9%)	5 (2.4%)
Withdrawal of Consent	7 (3.3%)	7 (3.3%)
Non-Compliant	1 (0.5%)	2 (1.0%)
Lost to Follow-up	0	1 (0.5%)
Lack of Efficacy	3 (1.4%)	0
Disallowed Concurrent Medication	1 (0.5%)	2 (1.0%)
Investigator Decision	2 (0.9%)	1 (0.5%)
Protocol Violation	3 (1.4%)	2 (1.0%)
Other	3 (1.4%)	1 (0.5%)

Discontinuation prior to Month 3 rate ~ 15% (in ROCKET 1, 2 and 4)

++Data on File
Based on Rocket 4 Topline 3-month and 6-month safety, Rocket 1 3-month, Rocket 2 3-month

Safety/Tolerability Overview of Rhopressa™ (Topline 6-Month)

- There were no drug-related serious adverse events (SAEs)
- There was no evidence of treatment-related systemic effects (e.g., clinical laboratory or hematology values, heart rate or blood pressure)
- The most common adverse event was conjunctival hyperemia with ~48% incidence and was scored as mild for ~75% of the patients
  - ~ 20% of all patients had hyperemia at baseline
  - Only ~10% of patients had hyperemia on each study visit day from week 2 to month 6
- Other ocular AEs
  - AEs occurring in ~5-25% of subjects receiving Rhopressa™ included: cornea verticillata, conjunctival hemorrhage, lacrimation increased, erythema of eyelid and vision blurred

++Data on File
Based on Rocket 4 Topline 6-month safety

Rhopressa™ Phase 3 Safety Profile (Topline 6-Month)

Adverse Events (≥5% in any group)	Rhopressa™ QD N = 351	Timolol BID N = 357
Eye Disorders		
Conjunctival Hyperemia	168 (47.9%)	33 (9.2%)
Cornea Verticillata	86 (24.5%)	0 (0.0%)
Conjunctival Hemorrhage	56 (16.0%)	11 (3.1%)
Lacrimation Increased	26 (7.4%)	5 (1.4%)
Erythema of Eyelid	26 (7.4%)	2 (0.4%)
Vision Blurred	22 (6.3%)	4 (1.1%)
Administration Site Conditions		
Instillation Site Pain	83 (23.6%)	92 (25.8%)
Instillation Site Erythema	36 (10.3%)	4 (1.1%)

Patients with known contraindications or hypersensitivity to timolol were excluded

++Data on File
Based on Rocket 4 Topline 6-month safety

No Change in Mean Hyperemia Score Over Time (Topline 6-Month)



- Hyperemia severity did not increase with continued dosing
- Hyperemia was sporadic
  - Only ~10% of patients had hyperemia on each study visit day from week 2 to month 6 (similar to the rates seen 12-month ROCKET 2)
- ~ 20% of all patients had hyperemia at baseline (similar to the rates seen in ROCKET 1 and 2)
- *Only ~4% of all patients discontinued due to hyperemia*

++Data on File
Based on Rocket 4 Topline 6-month safety

When Present, ~75% of Rhopressa™ Hyperemia Graded as Mild



Grade	Image	Description
0		None/Normal
1		Mild
2		Moderate
3		Severe

For illustrative purposes only

++Data on File
Based on Rocket 4 Topline 6-month safety

Timolol Caused Statistically Significant Reduction in Heart Rate (Rocket 4)



- Timolol
  - reduced mean heart rate by 2 - 3 beats per minute (average across all patients; $p < 0.0001$)
  - maximum change from baseline ~40 beats per minute
- Despite all measures to exclude patients with possible negative sensitivity to beta-blockers

++Data on File
Based on Rocket 4 Topline 6-month safety

Rhopressa™ Achieved Non-Inferiority in the Primary Efficacy Analysis for Baseline IOP < 25 mmHg and Maintained Stable Efficacy

Mean IOP at Each Time Point (PP) – Topline 6-Month



- Rhopressa™ performance remained within the non-inferiority range

++Data on File
Based on Rocket 4 Topline 6-month safety

Rhopressa™ Achieved Non-Inferiority for Baseline IOP < 27 mmHg and Maintained Stable Efficacy

Mean IOP at Each Time Point (PP) – Topline 6-Month



- Rhopressa™ performance remained within the non-inferiority range

++Data on File
Based on Rocket 4 Topline 6-month safety

Rhopressa™ Efficacy Stable through 6 Months 8am IOP

Baseline < 25 mmHg



Baseline < 27 mmHg



++Data on File
Based on Rocket 4 Topline 6-month 8am IOP

Rhopressa™ Once-Daily Performance Summary To Date

- Well researched in over 2,000 clinical patients
- 200+ Ophthalmologists' and Optometrists' experience with the new drug class
- Once-daily consistent efficacy demonstrated in 4 Phase 3 trials (Rocket 1, 2, 4 and Mercury 1)
- Stable efficacy through 12 months
- Well tolerated with no evidence of treatment-related serious or systemic effects
- Continue to explore additional differentiating attributes e.g., 24-hour IOP control, trabecular outflow and anti-fibrotic effects